How to cite: Gipp, I. “From Silos to Synergy: Data-Driven Strategies in Prostate Cancer Care.” September 15, 2025. Accessed Dec 2025. https://grandroundsinurology.com/from-silos-to-synergy-data-driven-strategies-in-prostate-cancer-care/
Summary
Ilya Gipp, MD, PhD, Chief Medical Officer for Oncology, GE Healthcare, Atlanta, Georgia, describes how prostate cancer care can move “from silos to synergy” by integrating imaging and data across the patient pathway. He focuses on magnetic resonance imaging (MRI) as an example of how imaging data can expand beyond diagnostic radiology.
Dr. Gipp explains that current deep learning techniques improve the quality of raw MRI data, resulting in clearer images, less noise, and quicker scan times. MRI improves segmentation of the prostate, bladder, and rectum, allowing for precise dosing, adaptive treatment strategies, and reduced risk of erectile dysfunction. MRI can also support early detection of radiation-related adverse effects and help assess treatment response.
Dr. Gipp advocates for broader integration with other data streams, such as positron emission tomography (PET) imaging and biomarkers. He notes that radiologists are increasingly expected to act as “multimodal data orchestrators,” combining imaging with molecular and clinical data to inform therapy selection and follow-up decisions.
Dr. Gipp shares that shifting from images as static pictures to structured, shareable data enables more precise risk stratification, adaptive treatment, and personalized care. He emphasizes that imaging data, when integrated, can improve continuity across the care pathway and support collaboration.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical cases and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Dr. Gipp received his medical degree from the Russian State Medical University and his doctorate in neuroradiology from the Moscow State University of Medicine and Dentistry.
In his role as medical officer, he drives company strategy for oncology and supports marketing, research, and development teams. He is an oncology subject matter expert and has experience in executive sales, product and field marketing, and clinical science. Before joining Philips in 2005, Dr. Gipp was a practicing physician and chair of a large imaging department. He has over 50 publications in peer-reviewed journals related to diagnostic imaging, oncology, and healthcare management. Dr. Gipp is passionate about hybridization in clinical and technical fields and enabling delivery of personalized care.
